My sense is that you cant worry too much
about the revenue and R&D expenses--I thought
I had scrawled down 7M revenue/12M loss
for Genset, 8M revenue and 32M loss for
Celera in the last quarter, so we don't
jibe--but not too important, they're not
in the same niche, the Celera Gorilla premium will
be paid if shotgunning makes them a leader.
I guess shotgunning is already proved for
smaller genomes and the world awaits the human
genome data, but as I've said, the real work
comes after the raw sequence is generated--and
plenty of companies and research centers
in on that.
For a marketcap of ~300M, and the consensus being
that Genset is the leading pharmacogenomics company,
all I can say is that it passes the sniff test for
value, but more DD is required, as long as it keeps
trending up, I'm okay. I think I said 2x book, but no,
cash is 34M and 90M total assets. Celera has a market
cap ten times my little Genset, amazing. I should go
snag the numbers for Incyte, MLNM, HGSI, and the
rest of the first and second tier genomics
companies, but that is more work than I wanted
to put into this. For now rising tide floating
all these boats.
Oh, I did find something interesting about Celera last
nite--"GeneTag", apparently they compiled their rat
database in just seven months.
I tell ya, between these SNP maps, gene expression
studies, new microarray technology--it is a bit much
for the stock hobbiest to digest. I understand the
appeal of jumping on TMF pick, they talk a good game
over there about due diligence, but I understand that
people are mainly just interested in being in the
right stocks at the right time and forgo the 'investing'
part--investors have a way of becoming traders when
they've made a profit anyway. |
